FindTrial
Sign In

anti-CD19 CAR-NK cells

BIOLOGICAL3 trials

Sponsors

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Acute Lymphocytic LeukemiaB-cell Prolymphocytic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large Cell LymphomaFollicular LymphomaMantle Cell LymphomaRefractory/Recurrent Central Nervous System LymphomaSystemic Lupus Erythematosus

Phase 1

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
NCT02892695
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Acute Lymphocytic Leukemia, B-cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia +3
Start: 2016-09-30End: 2019-09-30Target: 10Updated: 2016-12-06
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
RecruitingNCT06421701
Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySystemic Lupus Erythematosus
Start: 2024-08-01End: 2026-05-31Target: 10Updated: 2025-05-25
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Enrolling by invitationNCT06827782
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRefractory/Recurrent Central Nervous System Lymphoma
Start: 2025-03-01End: 2028-12-31Target: 42Updated: 2025-08-15

Related Papers

Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus.
2026-07-22